Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma

21 Jun 2021

Abstract excerpt

BACKGROUND: Medulloblastoma (MB) is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children undergoing treatment. Thus, there is an urgent need for improved, targeted therapies that minimize these harmful side...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34154646
DOI: 10.1186/s13073-021-00920-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastomaPMID 34154646Read ↗

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.Semantic proximity Read ↗

In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patientsSemantic proximity Read ↗

Integrative omics data analysis uncovers biomarker genes and potential candidate drugs for G3 medulloblastomaSemantic proximity Read ↗

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaSemantic proximity Read ↗

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaSemantic proximity Read ↗

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).Semantic proximity Read ↗

Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.Semantic proximity Read ↗

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological FeaturesSemantic proximity Read ↗

“PBT-SCREEN”, a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3Semantic proximity Read ↗

Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.Semantic proximity Read ↗

The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined TherapiesSemantic proximity Read ↗

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.